SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VPHM - Viropharma Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (2538)3/6/2012 5:42:18 PM
From: IRWIN JAMES FRANKEL1 Recommendation  Read Replies (1) of 2557
 
The study looks good. I would think subQ would be favored over IV by the patient all else being equal.

But it may not be equal.

Looks like the dose of C1 INH needs to be nearly double to get the same effect subQ.

Since the dose is expensive to harvest and process, and presumably much of that would be passed through, the higher cost may be a problem.

I also could not tell how big (ml) the injection is.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News